Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial

BACKGROUND: Standard administration of newer oral P2Y(12) inhibitors, including prasugrel or ticagrelor, provides suboptimal early inhibition of platelet aggregation (IPA) in patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention. We aimed to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gargiulo, Giuseppe, Esposito, Giovanni, Avvedimento, Marisa, Nagler, Michael, Minuz, Pietro, Campo, Gianluca, Gragnano, Felice, Manavifar, Negar, Piccolo, Raffaele, Tebaldi, Matteo, Cirillo, Plinio, Hunziker, Lukas, Vranckx, Pascal, Leonardi, Sergio, Heg, Dik, Windecker, Stephan, Valgimigli, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392586/
https://www.ncbi.nlm.nih.gov/pubmed/32795098
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.046928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392586/
https://www.ncbi.nlm.nih.gov/pubmed/32795098
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.046928

Ejemplares similares